EyePoint Inc.

03/02/2026 | Press release | Distributed by Public on 03/02/2026 06:43

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
EyePoint Inc. published this content on March 02, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 02, 2026 at 12:43 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]